NEW YORK (GenomeWeb News) – The Beijing Genomics Institute said yesterday that it plans to use its fleet of 120 Sanger and next-generation sequencing instruments to offer sequencing services to the global market.
In a statement, BGI said that it currently has more than 120 sequencers, which includes Applied Biosystems 3730xl sequencers, Amersham MegaBace sequencers, seven Illumina Genome Analyzers, and two ABI SOLiDs. The institute said these instruments enable a sequencing throughput of 250 million base pairs per day using Sanger and 4 billion base pairs per day using the next-generation instruments.
BGI said that it plans to provide these services at “dramatically reduced cost and improved speed,” but did not provide further details.
The institute said it considers its bioinformatics capabilities to be an advantage in the sequencing services market. BGI said it has more than 100 bioinformatics specialists, 2,000 CPUs, and more than 500 terabytes of storage.
In addition to sequencing, BGI said it will offer bioinformatics services including sequence data processing, sequence assembly, gene annotation, expression level research, EST and microarray analysis, SNP discovery, genotype and haplotype analysis, primer design, software development, system integration, structure modeling, and database and website construction.